Airbus reports completion of latest weekly share buyback transactions

Guillaume Faury Chief Executive Officer Airbus Airbus SE
Guillaume Faury Chief Executive Officer Airbus - Airbus SE
0Comments

Airbus SE has reported the details of its recent share buyback transactions conducted between 22 and 26 September 2025. The buybacks are part of a programme announced on 8 September 2025, intended to support future employee share ownership plans and equity-based compensation schemes.

The programme is carried out under the authority granted by shareholders at the Airbus Annual General Meeting on 15 April 2025. This authorisation allows the company’s Board of Directors to repurchase up to 10% of issued share capital.

During the specified period, Airbus executed daily purchases on the XPAR market. The number of shares bought each day ranged from 28,710 to 72,000, with daily weighted average purchase prices fluctuating between EUR 193.0117 and EUR 195.2561 per share. In total, Airbus acquired 264,657 shares at an average price of EUR 194.3649 per share.

A detailed breakdown of these transactions can be found on the company’s investor website at https://www.airbus.com/en/investors/share-price-and-information.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.